Key Highlights
- Total Revenue was USD 15.45 million against an estimate of USD 16.47 million.
- Net loss per share was USD 0.10 against an estimate of a USD 0.09 loss.
- Net loss was USD 33.47 million, compared with USD 10.47 million.
- Cash and cash equivalents were USD 126.40 million at September 30, 2026.
Invivyd (NASDAQ:IVVD) reported total revenue of USD 15.45 million for the third quarter of 2026, compared with USD 13.13 million in the third quarter of 2025, against an estimate of USD 16.47 million. The net loss was USD 33.47 million, compared with USD 10.47 million, and the net loss per share was USD 0.10, compared with USD 0.06, against an estimate of a USD 0.09 loss.
Costs and Operating Loss
Research and development expense was USD 18.74 million, compared with USD 8.05 million. Selling, general and administrative expense was USD 30.35 million, compared with USD 15.02 million, and cost of product revenue was USD 1.04 million. Total operating expenses were USD 50.13 million, compared with USD 24.15 million.
The loss from operations was USD 34.68 million, compared with USD 11.02 million.
Nine-Month Results
For the nine months ended September 30, 2026, total revenue was USD 43.48 million, compared with USD 36.22 million. The net loss was USD 119.26 million, compared with USD 41.42 million, and the net loss per share was USD 0.38, compared with USD 0.30.
Balance Sheet
Cash and cash equivalents were USD 126.40 million at September 30, 2026, compared with USD 226.69 million at December 31, 2025. Accounts receivable, net, were USD 12.19 million, compared with USD 13.92 million. Prepaid expenses and other current Assets were USD 9.25 million, compared with USD 6.86 million, and inventory was USD 25.23 million, compared with USD 25.50 million. Total current assets were USD 147.85 million, compared with USD 247.47 million.
The company describes itself as a biopharmaceutical company focused on monoclonal antibody therapies for the prevention and treatment of serious viral infectious diseases, beginning with SARS-CoV-2. In October 2025, it announced that the FDA cleared its Investigational New Drug application for VYD2311. In December 2025, it initiated DECLARATION, a Phase 3 randomized, triple-blind, placebo-controlled trial evaluating VYD2311 for the prevention of symptomatic, RT-PCR-confirmed COVID-19 at three months, and in June 2026 it announced completion of enrollment in the upsized trial.
In June 2026, the company announced initiation and completion of enrollment in LIBERTY, a Phase 3 trial designed to evaluate VYD2311, an mRNA-based COVID Vaccine and the two co-administered. The filing states that VYD2311 met all primary and secondary endpoints in LIBERTY. The FDA has granted Fast Track Designation for VYD2311 for the prevention of COVID-19 in individuals with underlying risk factors for progression to severe disease, and in October 2026 the company announced the initiation of FLINTLOCK, a Phase 2 trial in individuals with Long COVID or PVS.
Invivyd Q3 2026 Earnings: Key Takeaways
Invivyd reported third quarter 2026 total revenue of USD 15.45 million and a net loss of USD 33.47 million. Cash and cash equivalents were USD 126.40 million at September 30, 2026.


_11_20_2026_14_55_23_118425.jpg)



Please wait processing your request...